Literature DB >> 21918906

Challenges to the design and execution of controlled clinical studies of anticoagulants in patients with heparin-induced thrombocytopenia: lessons learned.

Steven W Boyce.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 21918906     DOI： 10.1007/s11239-011-0634-1

Source DB:  PubMed          Journal:  J Thromb Thrombolysis        ISSN： 0929-5305            Impact factor:   2.300


× No keyword cloud information.
  6 in total

1.  A randomized, open-label pilot study comparing desirudin and argatroban in patients with suspected heparin-induced thrombocytopenia with or without thrombosis: PREVENT-HIT Study.

Authors:  Steven W Boyce; Dennis F Bandyk; John R Bartholomew; James N Frame; Lawrence Rice
Journal:  Am J Ther       Date:  2011-01       Impact factor: 2.688

2.  Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies: results of the CHOOSE-ON trial.

Authors:  Andreas Koster; Cornelius M Dyke; Gabriel Aldea; Nicholas G Smedira; Harry L McCarthy; Solomon Aronson; Roland Hetzer; Edwin Avery; Bruce Spiess; A Michael Lincoff
Journal:  Ann Thorac Surg       Date:  2007-02       Impact factor: 4.330

3.  A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement.

Authors:  B I Eriksson; P Wille-Jørgensen; P Kälebo; P Mouret; N Rosencher; P Bösch; M Baur; S Ekman; D Bach; S Lindbratt; P Close
Journal:  N Engl J Med       Date:  1997-11-06       Impact factor: 91.245

4.  Prevention of thromboembolism with use of recombinant hirudin. Results of a double-blind, multicenter trial comparing the efficacy of desirudin (Revasc) with that of unfractionated heparin in patients having a total hip replacement.

Authors:  B I Eriksson; S Ekman; S Lindbratt; M Baur; D Bach; C Torholm; P Kälebo; P Close
Journal:  J Bone Joint Surg Am       Date:  1997-03       Impact factor: 5.284

5.  Treatment and prevention of heparin-induced thrombocytopenia: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition).

Authors:  Theodore E Warkentin; Andreas Greinacher; Andreas Koster; A Michael Lincoff
Journal:  Chest       Date:  2008-06       Impact factor: 9.410

6.  Off-pump coronary artery bypass with bivalirudin for patients with heparin-induced thrombocytopenia or antiplatelet factor four/heparin antibodies.

Authors:  Cornelius M Dyke; Gabriel Aldea; Andreas Koster; Nicholas Smedira; Edwin Avery; Solomon Aronson; Bruce D Spiess; A Michael Lincoff
Journal:  Ann Thorac Surg       Date:  2007-09       Impact factor: 4.330
  6 in total
  1 in total

1.  Design of the rivaroxaban for heparin-induced thrombocytopenia study.

Authors:  Lori-Ann Linkins; Theodore E Warkentin; Menaka Pai; Sudeep Shivakumar; Rizwan A Manji; Philip S Wells; Mark A Crowther
Journal:  J Thromb Thrombolysis       Date:  2014-11       Impact factor: 2.300
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.